Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | GBA1 | P04062 | 6/20 | 0.43 |
| ▸ | FUCA1 | P04066 | 4/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | GLB1 | P16278 | 2/20 | 0.43 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.36 |
| ▸ | PYGL | P06737 | 1/20 | 0.32 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30539390 | 1.00 | CCR5 (0.44) | CCR5GBA1FUCA1GLAGAA | |
| Hydrochloric Acid SCHEMBL6777912 | 0.97 | CCR5 (0.42) | CCR5GBA1FUCA1GLAGAA | |
| Hydrochloric Acid SCHEMBL6777914 | 0.97 | CCR5 (0.42) | CCR5GBA1FUCA1GLAGAA | |
| SCHEMBL5024292 | 0.88 | — | — | |
| SCHEMBL1726764 | 0.88 | — | — | |
| SCHEMBL12153077 | 0.88 | — | — | |
| SCHEMBL5024294 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL6773968 | 0.85 | CCR5 (0.47) | CCR5GBA1FUCA1GLAGAA | |
| Hydrochloric Acid SCHEMBL6773969 | 0.85 | CCR5 (0.47) | CCR5GBA1FUCA1GLAGAA | |
| SCHEMBL3721400 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110818704-B | Spiro bridged ring compounds, pharmaceutical compositions thereof and uses thereof | 广州市恒诺康医药科技有限公司 | 2023-08-01 | — | — | CN | disclosed |
| US-20190002452-A1 | FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO. LTD. (CN) | 2019-01-03 | — | — | US | disclosed |
| EP-3401315-A1 | FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | Guangzhou Henovcom Bioscience Co. Ltd. (CN) | 2018-11-14 | — | — | EP | disclosed |
| EP-3055313-B1 | CYCLIC THIENOURACIL CARBOXAMIDE AND ITS USE | Bayer Pharma AG (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-3055313-B1 | CYCLIC THIENOURACIL CARBOXAMIDE AND ITS USE | Bayer Pharma AG (DE) | 2017-11-22 | — | — | EP | disclosed |
| US-20170145029-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-25 | — | — | US | disclosed |
| US-20170145029-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | Bayer Pharma AG (DE) | 2017-05-25 | — | — | US | disclosed |
| US-9604996-B2 | Cyclic thienouracil-carboxamides and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-28 | — | — | US | disclosed |
| US-9604996-B2 | Cyclic thienouracil-carboxamides and use thereof | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-03-28 | — | — | US | disclosed |
| US-20160244461-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-08-25 | — | — | US | disclosed |
| EP-3055313-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2016-08-17 | — | — | EP | disclosed |
| WO-2015052065-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002452-A1 | FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF | NR1H4, FXR1, GPBAR1 | CCR5 471/4885GBA1 3003/4885FUCA1 1653/4885 |
| US-20160244461-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | TYMS, TPMT, PDF | CCR5 1187/4885GBA1 3927/4885FUCA1 4675/4885 |
| US-20170145029-A1 | CYCLIC THIENOURACIL-CARBOXAMIDES AND USE THEREOF | TYMS, TPMT, PDF | CCR5 1187/4885GBA1 3927/4885FUCA1 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.